Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

As described in the AMP SCZ introductory paper¹, several factors were taken into consideration in the selection of clinical measures and their time points. First, there needed to be existing evidence regarding their relevance for CHR outcomes….